GHELLI LUSERNA DI RORÀ, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 1990
EU - Europa 1482
AS - Asia 846
AF - Africa 140
OC - Oceania 6
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4473
Nazione #
US - Stati Uniti d'America 1981
GB - Regno Unito 538
VN - Vietnam 477
SE - Svezia 267
CN - Cina 221
DE - Germania 169
IT - Italia 151
IE - Irlanda 93
IN - India 90
FR - Francia 61
RU - Federazione Russa 55
TG - Togo 48
EE - Estonia 44
ZA - Sudafrica 42
BE - Belgio 40
NG - Nigeria 26
UA - Ucraina 25
CI - Costa d'Avorio 24
JO - Giordania 22
UZ - Uzbekistan 10
BG - Bulgaria 9
CA - Canada 9
IR - Iran 8
NL - Olanda 7
CH - Svizzera 5
GR - Grecia 5
JP - Giappone 5
AU - Australia 4
BR - Brasile 4
EU - Europa 4
FI - Finlandia 4
LB - Libano 3
AT - Austria 2
BD - Bangladesh 2
CZ - Repubblica Ceca 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
HR - Croazia 1
IL - Israele 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
SA - Arabia Saudita 1
SG - Singapore 1
TR - Turchia 1
Totale 4473
Città #
Southend 512
Chandler 343
Dong Ket 325
Fairfield 239
Ann Arbor 165
Houston 127
Wilmington 122
Woodbridge 121
Seattle 116
Ashburn 98
Cambridge 93
Dublin 93
Princeton 90
Lomé 48
Nanjing 44
Westminster 44
Padova 41
Brussels 39
Beijing 34
Bologna 34
Medford 34
Boardman 33
Berlin 27
Abeokuta 26
Falls Church 26
Abidjan 24
Amman 22
Redwood City 21
Bremen 20
Jinan 20
Saint Petersburg 19
Nanchang 18
Redmond 16
Hebei 14
Shenyang 14
Jiaxing 13
Changsha 11
San Diego 11
Sofia 9
Norwalk 8
Toronto 6
Zhengzhou 6
Augusta 5
Milan 5
Monmouth Junction 5
Paris 5
Andover 4
Hangzhou 4
Henderson 4
Leawood 4
Ningbo 4
San Francisco 4
São Paulo 4
Tianjin 4
Athens 3
Boydton 3
Dearborn 3
Haikou 3
Helsinki 3
Kunming 3
Lanzhou 3
Los Angeles 3
Phoenix 3
Taiyuan 3
Taizhou 3
Amsterdam 2
Auckland 2
Avellino 2
Bitola 2
Ceska 2
Chengdu 2
Den Haag 2
Dhaka 2
Frankfurt Am Main 2
Fremont 2
Kiev 2
Lausanne 2
London 2
Olalla 2
San Pedro 2
Shiraz 2
Tokyo 2
Vienna 2
Vijayawada 2
Winnipeg 2
Xian 2
Almaty 1
Bari 1
Bockhorn 1
Brisbane 1
Buffalo 1
Büdelsdorf 1
Changchun 1
Chongqing 1
Cranbury 1
Delhi 1
Des Moines 1
Deventer 1
Dubai 1
Gent 1
Totale 3267
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 202
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 167
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 163
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 163
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 161
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 158
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 147
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 135
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 121
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 115
Clec12a: A new AML stem cell-associated antigen 114
Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients 110
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 108
The cell cycle checkpoint inhibitors in the treatment of leukemias 107
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 106
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 106
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 104
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 103
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 102
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 102
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 101
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 101
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 95
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 93
Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions 90
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 90
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 90
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 89
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 83
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 82
The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias 81
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 81
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 81
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 80
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 79
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 79
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 77
null 75
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 73
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 70
The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway 69
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 68
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 66
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 66
You have accessMine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs 57
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 10
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 6
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 2
Totale 4628
Categoria #
all - tutte 7120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7120


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018108 0000 00 00 1208610
2018/2019297 24704 648 612 28563454
2019/20201145 17650258 12683 141137 163917345
2020/2021925 10440169 2324 1455 801352495
2021/20221024 128365885 10058 2348 4466189189
2022/20231065 15017567178 10289 3764 203000
Totale 4628